LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

LENSAR (NASDAQ:LNSR) released its quarterly earnings results on Tuesday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.28), FiscalAI reports. The firm had revenue of $14.13 million for the quarter, compared to the consensus estimate of $14.30 million. LENSAR had a net margin of 56.07% and a negative return on equity of 31,190.80%.

Here are the key takeaways from LENSAR’s conference call:

• Recurring revenue rose 17% to $12.6 million, procedure revenue increased 17%, and procedure volume grew 12% year over year. Recurring revenue made up 89% of total revenue, helping offset a 1% decline in total revenue as system sales fell against a strong prior-year comparison.
• LENSAR placed 10 ALLY systems, bringing its installed base to approximately 225, while market share edged up to 24.5%. The company said new robotic docking features are expected around the end of Q1 2027, potentially supporting further adoption.
• Gross margin improved to 58% from 42%, operating loss narrowed to about $1.4 million, and adjusted EBITDA turned positive at $1.7 million. GAAP net loss widened to $4.7 million, largely due to a non-cash warrant-liability expense.
• Management described overseas commercial activity as still recovering after distributor disruption, seasonal holidays, and reimbursement changes, and expects a gradual ramp into 2027. Executives also noted that U.S. cataract procedure volumes have recently been slightly softer.
• Cash and investments were $12.6 million at quarter-end, supplemented by a new $10 million revolving credit line. Management anticipates $1 million–$2 million of cash burn for the rest of 2026 and said it expects to move closer to break-even at some point in 2027.

LENSAR Stock Up 3.3%

Shares of LENSAR stock traded up $0.15 during trading hours on Thursday, reaching $4.73. 20,956 shares of the company’s stock were exchanged, compared to its average volume of 90,639. LENSAR has a 1 year low of $4.30 and a 1 year high of $12.94. The company has a market capitalization of $58.11 million, a P/E ratio of -11.83 and a beta of 1.03. The business has a fifty day moving average of $6.57 and a two-hundred day moving average of $7.25.

Analysts Set New Price Targets

Several research analysts recently issued reports on LNSR shares. Weiss Ratings upgraded shares of LENSAR from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 22nd. BTIG Research decreased their price objective on shares of LENSAR from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday. Lake Street Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of LENSAR in a research note on Thursday, August 13th. Wall Street Zen downgraded LENSAR from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Loop Capital set a $11.00 price objective on LENSAR in a research note on Monday, September 28th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $11.00.

LENSAR Company Profile

LENSAR, Inc. is a medical technology company focused on ophthalmic laser systems used in cataract surgery and other procedures involving the eye. The company develops and commercializes femtosecond laser technology designed to assist surgeons with key steps of cataract surgery, including corneal incisions, capsulotomy and lens fragmentation. Its product portfolio includes the LENSAR Laser System, which incorporates image-guidance and planning technologies intended to support precise, customized procedures.